| 摘要 |
<p>The invention provides methods of inhibiting the biological activity or the in vivo biological activity of CC-chemokines (including native MCP-3), such as methods of inhibiting inflammation, comprising administering to a host an effective amount of a CC-chemokine receptor antagonist of the present invention. In some embodiments, the invention may provide methods of modulating an immune response in a host, or treating inflammation or autoimmune disease in a host suffering from such diseases, comprising administering to the host an effective amount of a CC-chemokine receptor antagonist of the present invention. Another aspect of the present invention is directed to pharmaceutical compositions comprising an antagonistically effective amount of a CC-chemokine receptor antagonist of the present invention and a pharmaceutically acceptable carrier. In alternative aspects, the invention provides compounds and methods for cancer treatment that facilitate an effective immune response.</p> |
